Lilly CEO Blames Slower Innovation on Immigration, Tax Laws
This article is for subscribers only.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. Chief Executive Officer John Lechleiter told a technology conference today.
The pharmaceutical industry faces $1.3 billion in development costs for a single drug and had 95 Food and Drug Administration clearances in the past five years, the lowest in such a span since the late 1970s. The industry is in a six-year window when products that make up 40 percent of pharmaceutical sales lose patent protection, equivalent to a $100 billion loss in annual revenue, he said.